Canaccord Genuity lowers Passage Bio stock price target to $67 from $260

Passage Bio Inc. (PASG) saw Canaccord Genuity drastically cut its price target to $67 from $260, while retaining a "Buy" rating, following an "uneventful" Q2 2025 report and a serious adverse event in a patient from its PBFT02 gene therapy trial. This re-evaluation comes as the company prepares a 1-for-20 reverse stock split to meet Nasdaq listing requirements and navigates ongoing cash burn despite current liquidity. Despite these setbacks, Passage Bio is advancing its clinical program with amended protocols, planning new cohort enrollments, and reported positive interim data for PBFT02, with the next critical data readout anticipated in the first half of 2026.

Analysis

Passage Bio Inc. is navigating a period of significant clinical and financial recalibration, underscored by Canaccord Genuity's drastic price target reduction to $67.00 from $260.00. This revision was directly prompted by a serious adverse event (pulmonary embolism) in a patient from its PBFT02 gene therapy trial, which overshadowed an otherwise uneventful Q2 2025 report. Despite this major setback, Canaccord maintained a "Buy" rating, indicating a belief in the therapy's long-term potential if safety concerns are successfully addressed. The company's financial health presents a mixed picture; while it holds more cash than debt and maintains a solid current ratio of 3.05, InvestingPro data flags a rapid cash burn rate, a critical risk for a clinical-stage entity. To address its low share price, the company is executing a 1-for-20 reverse stock split to maintain Nasdaq listing compliance. Looking forward, the primary catalyst is the next data readout expected in the first half of 2026, which will be crucial for validating the amended trial protocol and assessing the therapy's viability, especially given the positive interim data showing sustained progranulin levels in treated patients.

Key Decisions for Investors

• Investors must weigh the high-risk profile, evidenced by the serious adverse event and subsequent 74% price target cut, against the high-reward potential suggested by Canaccord's maintained 'Buy' rating and positive interim biomarker data.
• Monitor the company's cash burn rate closely, as its rapid use of cash presents a significant long-term financing risk that could necessitate future dilution ahead of key clinical milestones.
• Consider that Passage Bio is an event-driven investment, with the next major catalyst being the clinical data readout in H1 2026, making any position highly sensitive to future trial results and safety updates.